Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

Comedian Jim Gaffigan, whose new stand-up special, 'The Skinny', premieres on Nov. 22 on Hulu, has lost 50 lbs. with the help ...

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

Three stocks that have not only been around for a century but have also been paying dividends for that long are Coca-Cola ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Whether these departments get the money will be decided later, but the Scene listened in on requests from the Department of ...

Investors can wait and see if the company delivers any improvement in Mounjaro and Zepbound’s sales in the fourth quarter.

We recently published a list of 10 Best Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to ...

Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...

Eli Lilly's Mounjaro joins list of obesity and diabetes drugs made popular by celebrities who lost weight The latest ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...